- Home
- FOLD vs OUT Comparison
FOLD vs OUT Comparison
Compare FOLD & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- OUT
- Stock Information
- Founded
- FOLD 2002
- OUT 2013
- Country
- FOLD United States
- OUT United States
- Employees
- FOLD N/A
- OUT N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- OUT Real Estate Investment Trusts
- Sector
- FOLD Health Care
- OUT Real Estate
- Exchange
- FOLD Nasdaq
- OUT Nasdaq
- Market Cap
- FOLD 2.9B
- OUT 2.4B
- IPO Year
- FOLD 2007
- OUT N/A
- Fundamental
- Price
- FOLD $6.12
- OUT $17.62
- Analyst Decision
- FOLD Buy
- OUT Buy
- Analyst Count
- FOLD 10
- OUT 8
- Target Price
- FOLD $16.22
- OUT $18.73
- AVG Volume (30 Days)
- FOLD 5.5M
- OUT 1.4M
- Earning Date
- FOLD 08-07-2025
- OUT 08-05-2025
- Dividend Yield
- FOLD N/A
- OUT 6.85%
- EPS Growth
- FOLD N/A
- OUT N/A
- EPS
- FOLD N/A
- OUT 1.53
- Revenue
- FOLD $543,141,000.00
- OUT $1,813,100,000.00
- Revenue This Year
- FOLD $19.87
- OUT N/A
- Revenue Next Year
- FOLD $23.15
- OUT $2.85
- P/E Ratio
- FOLD N/A
- OUT $11.48
- Revenue Growth
- FOLD 28.25
- OUT N/A
- 52 Week Low
- FOLD $5.51
- OUT $12.95
- 52 Week High
- FOLD $12.65
- OUT $19.98
- Technical
- Relative Strength Index (RSI)
- FOLD 51.42
- OUT 66.86
- Support Level
- FOLD $5.66
- OUT $16.75
- Resistance Level
- FOLD $6.45
- OUT $17.71
- Average True Range (ATR)
- FOLD 0.21
- OUT 0.47
- MACD
- FOLD 0.07
- OUT 0.13
- Stochastic Oscillator
- FOLD 64.89
- OUT 95.80
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The Company generates revenue in the form of rental income by allowing other companies to advertise on its properties and structures under short-term contracts. Outfront Media segments its operations into the United States and International units. Although it also owns assets in Canada and Latin America, the company derives the vast majority of its revenue from billboard advertising agreements in the U.S. Roughly half of the U.S. division's revenue comes from its displays in the New York City and Los Angeles markets. Outfront Media's customers include entities within the retail, television, healthcare, and entertainment industries.